Cybin Announces At-the-Market Equity Program of Up to US$35 Million
On August 23, 2023, Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) (the “Company” or “Cybin”), a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options, announced the renewal of its previously established at-the-market equity program (“ATM Program”) that allows Cybin to issue and sell up to US$35 million of common shares from treasury to the public, from time to time, through Cantor Fitzgerald Canada Corporation and Cantor Fitzgerald & Co. (collectively, the "Agents").
Distributions under the ATM Program will be made pursuant to the terms and conditions of an "at-the-market equity" distribution agreement dated August 23, 2023, between Cybin and the Agents. The ATM Program is qualified by way of a prospectus supplement dated August 23, 2023, to Cybin's short-form base shelf prospectus dated August 17, 2023.
Cybin intends to use the net proceeds from sales of shares under the ATM Program, if any, for growth opportunities and working capital initiatives.
Aird & Berlis represented Cybin with a team led by Sherri Altshuler and including Adria Leung Lim, Sean Green and Meredith McCann (Capital Markets).
-
BioFull bio
Sherri earns the trust of her clients by adeptly managing complex and time-sensitive corporate finance transactions and by providing relevant, busines...
-
BioFull bio
Adria enjoys the fast-paced and challenging nature of securities law.
-
BioFull bio
When it comes to complex capital markets transactions, Sean provides clients with the support they need to navigate corporate laws and achieve their b...
-
BioFull bio
When it comes to complex capital markets transactions or navigating regulatory requirements, Meredith’s primary focus is on her clients’ i...
